Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders
Field | Value | Language |
dc.contributor.author | Leung, Sharon SY | |
dc.contributor.author | Parumasivam, Thaigarajan | |
dc.contributor.author | Gao, Fiona G | |
dc.contributor.author | Carrigy, Nicholas B | |
dc.contributor.author | Vehring, Reinhard | |
dc.contributor.author | Finlay, Warren H | |
dc.contributor.author | Morales, Sandra | |
dc.contributor.author | Britton, Warwick J | |
dc.contributor.author | Kutter, Elizabeth | |
dc.contributor.author | Chan, Hak-Kim | |
dc.date.accessioned | 2019-05-17 | |
dc.date.available | 2019-05-17 | |
dc.date.issued | 2017-04-15 | |
dc.identifier.uri | http://hdl.handle.net/2123/20424 | |
dc.description.abstract | This study aimed to develop inhalable powders containing phages active against antibiotic-resistant Pseudomonas aeruginosa for pulmonary delivery. A Pseudomonas phage, PEV2, was spray dried into powder matrices comprising of trehalose (0–80%), mannitol (0–80%) and L-leucine (20%). The resulting powders were stored at various relative humidity (RH) conditions (0, 22 and 60% RH) at 4 ºC. The phage stability and in vitro aerosol performance of the phage powders were examined at the time of production and after 1, 3 and 12 months storage. After spray drying, a total of 1.3 log titer reduction in phage was observed in the formulations containing 40%, 60% and 80% trehalose, whereas 2.4 and 5.1 log reductions were noted in the formulations containing 20% and no trehalose, respectively. No further reduction in titer occurred for powders stored at 0 and 22% RH even after 12 months, except the formulation containing no trehalose. The 60% RH storage condition had a destructive effect such that no viable phages were detected after 3 and 12 months. When aerosolised, the total lung doses for formulations containing 40%, 60% and 80% trehalose were similar (in the order of 105 pfu). The results demonstrated that spray drying is a suitable method to produce stable phage powders for pulmonary delivery. A powder matrix containing ≥ 40% trehalose provided good phage preservation and aerosol performances after storage at 0 and 22 % RH at 4 ºC for 12 months. | en_AU |
dc.description.sponsorship | This work was financially supported by the Australian Research Council (Discovery Project DP150103953). Authors are grateful to Tony Smithyman of Special Phage Services for his valuable discussion and advice. SSY Leung is a research fellow supported by the University of Sydney. T Parumasivam is a recipient of the Malaysian Government Scholarship. H-K Chan is funded by the National Institutes of Health (NIH Project no.1R21AI121627-01) and WJ Britton by the National Health and Medical Research Council Centre of Research Excellence in Tuberculosis Control (APP1043225). | en_AU |
dc.language.iso | en_AU | en_AU |
dc.publisher | Elsevier | en_AU |
dc.relation | ARC DP150103953, NIH Project no.1R21AI121627-01, NHMRC APP1043225, University of Sydney Research Fellowship, Malaysian Government Scholarship | en_AU |
dc.subject | Phage | en_AU |
dc.subject | PEV2 | en_AU |
dc.subject | pulmonary infection | en_AU |
dc.subject | multi-drug resistance | en_AU |
dc.subject | spray drying | en_AU |
dc.subject | MDR | en_AU |
dc.title | Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders | en_AU |
dc.type | Article | en_AU |
dc.subject.asrc | FoR::110203 - Respiratory Diseases | en_AU |
dc.subject.asrc | FoR::110309 - Infectious Diseases | en_AU |
dc.subject.asrc | FoR::111504 - Pharmaceutical Sciences | en_AU |
dc.identifier.doi | https://doi.org/10.1016/j.ijpharm.2017.01.060 | |
dc.type.pubtype | Pre-print | en_AU |
Associated file/s
Associated collections